Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Feb 24, 2021 9:02pm
110 Views
Post# 32654723

RE:RE:RE:RE:I am getting the impression

RE:RE:RE:RE:I am getting the impressionWhile they may not think it, one of the ways these funds all work is to chat about positions with their pals.  Especially the ones they've worked with in the past.  In the old days, brokers used to actually sponsor "idea dinners" where we'd all pitch.  They still do it but much more on the sly now. 

It would be typical in their playbook to eventually (meaning once there's solid factual evidence what they have is going to be a success) to push a few analysts and firms they know to at least "look" at it.  Some may.  From their size, they aren't one of the huge players, so they may not have as much sway as the top tier guys on that point.

The other part of their playbook also happens once the stocks started to move and there's a very fundamental proof it will be a solid long-term idea.  So maybe once they have some trial results and the stocks already up 100%, then they mention it to some of the old colleagues and pals to take a look, or that it's one of their top ideas, etc...   It allows them to boast a bit and feel like BSDs chatting about a new idea that's doubled that they've never heard of and it's doing some first in class innovative things around PDS and has a NASH P3 ongoing, etc... 

So, yes, you can get that if they are one of those kind of firms. Let's watch the filings, but it wouldn't shock me that in a year you see it popping up in other guys portfolios. It's not something I think you'd see until there's that hard data in humans to validate the thesis. 

qwerty22 wrote:

Let's say Wino is right about these guys knowing other guys with deep pockets. Btw do you think that's a good description of them? Has the company in effect simply tried to buy some credibility thru Soleus? Is the financing just the heavy price they paid for that. Can Soleus be big enough to effectively do for THTX what you've wanted the company to do for a long time and generate credibility in the US? Could Soleus be enough to bring analysts sniffing around to see what's going on? If these are value-added investors how much do you have to pay for that value?

Are Soleus big enough to get the ball rolling on all the things this board wanted from the US? Am I over-egging this?

 

 

SPCEO1 wrote: Well, well well, we closed at $3.15 on THTX - which was the price the stock closed at just before the deal was announced. Strikingly convenient timing. 

Yes, it was very weird deal, largely because it was a give away to our new friends at Soleus and the others who were allowed to participate in the deal. Long time, loyal shareholders like ourselves were not given even the courtesy of a call to see if we might be interested in participating in the offering. I am pretty sure Soleus is in this for a big move in the stock and not looking for any short term trade. They are science based and they clearly are interested in seeing the science play out on the cancer front since that is their area of expertise. 

Given the wildly bullish environment, the deal was clearly the worst possible deal for legacy shareholders that could have been done. It really could not have been that hard to get a much better deal done and it is nearly impossile to concieve a good reason for why a better deal waas not done. Kudo's to Soleus and others for negotiatiing a great deal for themselves but it should come as no surprise that legacy shareholders are seriously disappointed by just about every aspect of this offering. They don't get much uglier than this particular offering. 
 

 

ANALIAS00 wrote: Well....that would be a weird "deal". Do you believe or not to TH's science? You could have suggest the same deal at 4$ (can) and do the same (actions, initiatives, etc) to bring the share price up without deluting and upset all existing shareholders. I am sure they were not jumping into this stock for a possible 15 or 20% profit on the stock. As us, they certainly expect the SP to double up eventually. So to me it is still a weird deal that would be interesting to fully understand in what kind of situation TH was to believe this was the best deal they were able to sign.
SPCEO1 wrote: our new large shareholder may have had a deal with THTX that if they accepted the low ball share offering price, they would do their best to average up a nd get the share price back to where it was just before the deal by the time tomorrow's confernce call is held.

 

 




<< Previous
Bullboard Posts
Next >>